Publisher
Springer Science and Business Media LLC
Reference16 articles.
1. Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203–1210. doi: 10.1016/S0140-6736(12)61763-2
2. Luminari S, Goldaniga M, Cesaretti M et al (2016) A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma. LeukLymphoma Apr 57(4):880–887
3. Common Terminology Criteria for Adverse Events (CTCAE) (2009) Version 4.0, published: May 28, 2009 (v4.03: June 14, 2010)
4. Link H, Nietsch J, Kerkmann M et al (2016) Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy-a representative sample survey in Germany. Support Care Cancer 24(1):367–376
5. Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100:228–237
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献